<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71980">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168686</url>
  </required_header>
  <id_info>
    <org_study_id>ADVM-043-01</org_study_id>
    <nct_id>NCT02168686</nct_id>
  </id_info>
  <brief_title>Safety Study of Gene Transfer Vector to Treat Alpha1-antitrypsin (A1AT) Deficiency</brief_title>
  <official_title>A Phase 1/2, Randomized, Open-label, Parallel Group, Multicenter, Dose Escalation Study Designed to Evaluate the Safety and Preliminary Efficacy of the ADVM-043 Gene Transfer Vector Following Intrapleural (IP) or Intravenous (IV) Infusion Administration in Patients With Alpha1-antitrypsin (A1AT) Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adverum Biotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and primary efficacy of a gene transfer
      vector (drug) for the treatment of alpha1-antitrypsin (A1AT) deficiency. The study uses an
      experimental drug (ADVM-043 also known as AAVrh.10halpha1AT) to deliver a gene (gene
      transfer) to treat the signs and symptoms of A1AT deficiency. Unlike other drugs, this one
      is made of a virus called adeno-associated virus (AAV). In this study, the AAV acts as the
      vehicle used to carry the A1AT gene into the lung cells so it can treat the cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1/2, randomized, open-label, parallel group, multicenter, dose-escalation study
      is designed to evaluate the safety and preliminary efficacy of the ADVM-043 gene transfer
      vector following intrapleural (IP) administration in patients with A1AT deficiency. As a
      comparator to the IP route of administration, an equal number of patients with A1AT
      deficiency will be administered the ADVM-043 vector by intravenous (IV) infusion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in adverse events as a measure of safety and tolerability</measure>
    <time_frame>Screening, pre-therapy, 3, 6, and 12 months post-vector administration</time_frame>
    <description>Safety will be assessed by vital signs, EKG, blood work, immunological responses, chest x-ray and lung function test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in therapeutic alveolar ELF and serum levels of a1AT</measure>
    <time_frame>Screening, pre-therapy, 3, 6, and 12 months post-vector administration</time_frame>
    <description>Efficacy will be assessed by bloodwork and bronchoscopy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>intrapleural administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ADVM-043</intervention_name>
    <description>gene transfer vector administration</description>
    <arm_group_label>intrapleural administration</arm_group_label>
    <arm_group_label>intravenous administration</arm_group_label>
    <other_name>AAVrh.10halpha1AT</other_name>
    <other_name>AAVrh.10hA1AT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of providing informed consent;

          -  A1AT genotype of ZZ or Z Null;

          -  Males and females 18 years and older;

          -  Patients not receiving A1AT protein augmentation therapy (PAT) for at least 2 months
             prior to the Screening visit or for individuals receiving A1AT PAT at Screening, the
             augmentation therapy should be stopped for 2 months to allow for augmentation therapy
             to wash out;

          -  Serum A1AT level &lt;11 µM;

          -  Mild to moderately severe emphysema as quantitated by HRCT;

          -  Lung function parameters consistent with the presence of emphysema - only individuals
             with an FEV1 &gt;1.2 L/sec;

          -  Fertile men and women of child bearing potential who agree to use barrier birth
             control measures to prevent pregnancy during and for 1 month following the
             administration of vector;

          -  Willingness to participate in the study.

        Exclusion Criteria:

          -  Individuals who do not meeting the inclusion criteria;

          -  Individuals receiving systemic corticosteroids or other immunosuppressive
             medications;

          -  Individuals with an immunodeficiency disease, or evidence of active infection of any
             type, including HIV;

          -  Evidence of major central nervous system, major psychiatric, musculoskeletal or
             immune disorder;

          -  Evidence of chronic hepatitis B or C infection;

          -  History of myocardial infarction or cancer within the past 5 years (other than
             treated basal cell carcinoma of the skin);

          -  Evidence of infection defined by elevated white blood cell count, temperature &gt;38.5°C
             or infiltrate on chest x-ray;

          -  Creatinine &gt;2 mg/dL;

          -  Alanine transaminase &gt;67.5 U/L;

          -  Aspartate transferase &gt;67.5 U/L;

          -  Bilirubin (total) &gt;1.9 mg/dL;

          -  Bilirubin (direct) &gt;0.6 mg/dL;

          -  AAVrh.10 neutralizing antibody titre &gt;1:5 at Screening;

          -  Other significant laboratory abnormalities that may compromise the patient's safety
             by participation in this study;

          -  Pregnant or lactating females;

          -  Current alcohol or drug abuse;

          -  Any history of allergies to xylocaine, lidocaine, versed, valium, atropine,
             pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic;

          -  Individuals receiving other experimental medications or participating in another
             clinical trial for at least 3 months prior to entry to the study;

          -  Active smokers of cigarettes, or any other tobacco use, e-cigarettes or other
             recreational inhalant(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlton Strange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fredrich Kueppers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Hospital, Philadelphia, PA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Fiankan</last_name>
    <phone>+1 (650) 665-7025</phone>
    <email>cfiankan@adverum.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvia Johnson</last_name>
      <phone>215-707-1359</phone>
      <email>Sylvia.Johnson@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Fredrich Kueppers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Woodford</last_name>
      <phone>843-792-6280</phone>
      <email>woodfordd@musc.ed</email>
    </contact>
    <contact_backup>
      <last_name>Gwen Blanton</last_name>
      <phone>843-792-8438</phone>
      <email>blantonm@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charlton Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 29, 2016</lastchanged_date>
  <firstreceived_date>June 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alpha1-antitrypsin deficiency</keyword>
  <keyword>alpha1AT</keyword>
  <keyword>A1AT</keyword>
  <keyword>ADVM-043</keyword>
  <keyword>gene therapy</keyword>
  <keyword>gene transfer vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
